Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States

Abstract

One of the major projects of the Worldwide Network for Blood and Marrow Transplantation (WBMT) is to promote hematopoietic stem cell transplantation (HSCT) in emerging countries in the world. For these countries, HLA haploidentical HSCT (haplo-HSCT) from family members is an attractive approach because of its cost effectiveness. To learn the current status, including recent trends, of haplo-HSCT, the WBMT invited speakers from major transplant centers in 3 regions (Asia, Europe, and North America) to present at its annual WBMT Joint Session. This article represents the direct reports from these 3 speakers in addition to introductions by 2 WBMT speakers who address data from the Global Transplant Activity survey. It must be emphasized, however, that certain promising results of haplo-HSCT presented in this article were obtained at well-experienced institutes.

Depletion of αβ+ T cells for a haploidentical hematopoietic stem cell transplantation in children

“…Acute GVHD remains the main cause of TRM, and chronic GVHD is one of the major factors significantly compromising quality of life of children receiving an allogeneic HCT. Recent advances with effective ex vivo depletion of T cells or unmanipulated in vivo regulation of T cells have significantly improved the outcome of a haploidentical HCT . Establishment of the optimal ex vivo T cell depletion technique to prevent GVHD is an important issue for an HCT from haploidentical relatives.…”

“…Recent advances with effective ex vivo depletion of T cells or unmanipulated in vivo regulation of T cells have significantly improved the outcome of a haploidentical HCT. [1][2][3][4][5][6][7][8] Establishment of the optimal ex vivo T cell depletion technique to prevent GVHD is an important issue for an HCT from haploidentical relatives. The ex vivo methods for removal of T cells have evolved from the selection of CD34 1 hematopoietic stem cell progenitors to the depletion of CD3 1 cells and to the depletion of ab 1 T cells more recently.…”

Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course

“…Notable improvements in haplo‐HSCT now allow this technique to be widely performed when patients with haematological malignancies lack a suitable HLA‐MSD (Chang & Huang, ; Chang et al , ; Apperley et al , ). In recent years, our group established a T‐cell replete myeloablative haplo‐HSCT technique that involves G‐CSF and ATG.…”

“…Five of these patients ultimately cleared HEV, two died of pneumonia during HEV infection, and no patients died directly as a result of HEV infection. Notable improvements in haplo-HSCT now allow this technique to be widely performed when patients with haematological malignancies lack a suitable HLA-MSD (Chang & Huang, 2012;Chang et al, 2014;Apperley et al, 2016). In recent years, our group established a T-cell replete myeloablative haplo-HSCT technique that involves G-CSF and ATG.…”

“…Haploidentical haematopoietic stem cell transplantation (haplo‐HSCT) offers rapid and almost universal donor availability. It has therefore been accepted worldwide as an alternative treatment for patients with haematological diseases who do not have a completely human leucocyte antigen (HLA)‐matched sibling donor (MSD) or who require urgent transplantation (Chang & Huang, ; Chang et al , ; Apperley et al , ). Haplo‐HSCT produces outcomes comparable to those achieved in HLA MSD transplantation (Wang et al , , ).…”